|
MedChemExpress
defactinib Defactinib, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/defactinib/product/MedChemExpress Average 95 stars, based on 1 article reviews
defactinib - by Bioz Stars,
2026-02
95/100 stars
|
Buy from Supplier |
|
MedChemExpress
fak inhibitor Fak Inhibitor, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/fak inhibitor/product/MedChemExpress Average 94 stars, based on 1 article reviews
fak inhibitor - by Bioz Stars,
2026-02
94/100 stars
|
Buy from Supplier |
|
TargetMol
defactinib ![]() Defactinib, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/defactinib/product/TargetMol Average 94 stars, based on 1 article reviews
defactinib - by Bioz Stars,
2026-02
94/100 stars
|
Buy from Supplier |
|
TargetMol
cytochalasin d ![]() Cytochalasin D, supplied by TargetMol, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/cytochalasin d/product/TargetMol Average 93 stars, based on 1 article reviews
cytochalasin d - by Bioz Stars,
2026-02
93/100 stars
|
Buy from Supplier |
Journal: Signal Transduction and Targeted Therapy
Article Title: Interaction between CDC6 and Tmod3 accelerates resistance to paclitaxel through focal adhesion assembly
doi: 10.1038/s41392-025-02490-7
Figure Lengend Snippet: Tmod3 and CDC6 accelerate focal adhesion assembly. a Paxillin and actin filaments in wild type cells and CDC6-KO cells (n = 10 images; ****P < 0.0001). Scale bar, 10 µm. b Changes in the protein expression of CDC6, paxillin and p-paxillin in A549/PTX wild-type and CDC6-KO cells (n = 3; ****P < 0.0001). c Changes in the protein expression of CDC6, paxillin and p-paxillin after treatment with different concentrations of Blebb and CytoD for 72 h (n = 3; ****P < 0.0001, ## P < 0.01, #### P < 0.0001). d , e Paxillin in Tmod3- and Tmod1-depleted cells was visualized via confocal microscopy (n = 10 images; ****P < 0.0001). Scale bar, 10 µm. f , g Wild-type and CDC6-KO cells were exposed to CytoD (5 μM) for 3 h. The cells were fixed at the indicated time points after CytoD washout, stained with phalloidin and paxillin, and visualized via confocal microscopy. Scar bar, 10 μm. h , i Immunofluorescence analysis of paxillin in HeLa/CDC6 EGFP cells after nocodazole (10 μM) treatment for 4 h which were then washed out for the indicated times. Scale bar, 10 μm. Wild-type cells (dotted line) and CDC6 EGFP -overexpression cells (solid line) are magnified. j A549/PTX cells were exposed to paclitaxel, defactinib or a combination of paclitaxel and defactinib for 72 h. Cell viability was determined via the MTT assay (n = 3; ***P < 0.001). The data are presented as the means ± SDs
Article Snippet: Norcantharidin (Aladdin, N159736), reversine (TargetMol, T1825, 0.5 μM), AZ3146 (TargetMol, T2689, 1 μM), blebbistatin (TargetMol, T21550 ), cytochalasin D (Aladdin, C102396), and
Techniques: Expressing, Confocal Microscopy, Staining, Immunofluorescence, Over Expression, MTT Assay